Intermediates of Krebs cycle correct the depression of the whole body oxygen consumption and lethal cooling in barbiturate poisoning in rat.
Rats poisoned with one LD50 of thiopental or amytal are shown to increase oxygen consumption when intraperitoneally given sucinate, malate, citrate, alpha-ketoglutarate, dimethylsuccinate or glutamate (the Krebs cycle intermediates or their precursors) but not when given glucose, pyruvate, acetate, benzoate or nicotinate (energy substrates of other metabolic stages etc). Survival was increased with succinate or malate from control groups, which ranged from 30-83% to 87-100%. These effects were unrelated to respiratory depression or hypoxia as judged by little or no effect of succinate on ventilation indices and by the lack of effect of oxygen administration. Body cooling of comatose rats at ambient temperature approximately 19 degrees C became slower with succinate, the rate of cooling correlated well with oxygen consumption decrease. Succinate had no potency to modify oxygen consumption and body temperature in intact rats. A condition for antidote effect of the Krebs intermediate was sufficiently high dosage (5 mmol/kg), further dose increase made no odds. Repeated dosing of succinate had more marked protective effect, than a single one, to oxygen consumption and tended to promote the attenuation of lethal effect of barbiturates. These data suggest that suppression of whole body oxygen consumption with barbiturate overdose could be an important contributor to both body cooling and mortality. Intermediates of Krebs cycle, not only succinate, may have a pronounced therapeutic effect under the proper treatment regimen. Availability of Krebs cycle intermediates may be a limiting factor for the whole body oxygen consumption in barbiturate coma, its role in brain needs further elucidation.
Ivnitsky
Jury Ju
JJ
Military Toxicology and Medical Protection, Military Medical Academy, ul. Lebedeva 6, 194044 St. Petersburg, Russia. neugierig@mail.ru
Schäfer
Timur V
TV
Malakhovsky
Vladimir N
VN
Rejniuk
Vladimir L
VL
D000654:Amobarbital / Q000008:administration & dosage / Q000506:poisoning; D000818:Animals; D000931:Antidotes / Q000008:administration & dosage / Q000627:therapeutic use*; D001831:Body Temperature / Q000187:drug effects; D002952:Citric Acid Cycle / Q000502:physiology*; D003128:Coma / Q000139:chemically induced / Q000517:prevention & control; D005260:Female; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000506:poisoning; D007035:Hypothermia / Q000503:physiopathology / Q000517:prevention & control*; D007274:Injections, Intraperitoneal; D010101:Oxygen Consumption / Q000187:drug effects* / Q000502:physiology; D011041:Poisoning / Q000150:complications / Q000378:metabolism* / Q000517:prevention & control; D051381:Rats; D019802:Succinic Acid / Q000378:metabolism / Q000627:therapeutic use; D013858:Thiobarbiturates / Q000008:administration & dosage / Q000506:poisoning*; D013874:Thiopental / Q000008:administration & dosage / Q000506:poisoning
D000931:Antidotes; D006993:Hypnotics and Sedatives; D013858:Thiobarbiturates; D019802:Succinic Acid; D000654:Amobarbital; D013874:Thiopental